Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation

The gene encoding for p16ink4a, a negative regulator of transition between G1 and S phase, is homozygously deleted in a large proportion of acute lymphoblastic leukaemias (ALL). Transfer of p16ink4a gene in several solid tumour cell lines with functional pRb and lacking both p16ink4a alleles has resulted in a dramatic reduction of cell proliferation, and the aim of this work was to confirm this effect in leukaemic (especially ALL) cell lines. We tested the proliferation in liquid medium and in soft agar after transfer of p16ink4a gene by a retroviral vector in leukaemic cell lines with homozygous p16ink4a gene deletion (K562, CEM, Jurkat cell lines) or with p16ink4a gene hemizygous deletion and a point mutation inactivating the remaining allele (HL60 cell line). The viral titre obtained after transfection of PA317 amphotropic packaging cell line, which has a p16ink4a gene homozygous deletion, was low, suggesting that p16ink4a gene expression could impair viral production of retroviral packaging cell lines derived from the NIH3T3 cell line.

[1]  R. Jamal,et al.  Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level. , 1996, Leukemia.

[2]  H. Haddada,et al.  Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. , 1996, Leukemia.

[3]  Carl W. Miller,et al.  Structural integrity of the cyclin‐dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias , 1995, British journal of haematology.

[4]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[5]  J. Roth,et al.  Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. , 1995, Cancer research.

[6]  C. Bartram,et al.  Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.

[7]  C. Bréchot,et al.  Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. , 1995, Leukemia.

[8]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[9]  J. Bartek,et al.  Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. , 1995, Oncogene.

[10]  M. Tomonaga,et al.  Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. , 1995, Blood.

[11]  F. Mandelli,et al.  Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. , 1995, Blood.

[12]  J. Goldman,et al.  Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. , 1995, Blood.

[13]  W. Cavenee,et al.  Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. , 1995, Cancer research.

[14]  J. Griffin,et al.  Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. , 1995, Oncogene.

[15]  M. Yuille,et al.  Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.

[16]  B. Quesnel,et al.  p16 gene homozygous deletions in acute lymphoblastic leukemia. , 1995, Blood.

[17]  G. Peters,et al.  Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.

[18]  R. DePinho,et al.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.

[19]  F. Sigaux,et al.  Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. , 1994, Blood.

[20]  A. Schulze,et al.  Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1. , 1994, Oncogene.

[21]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[22]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[23]  A. Okamoto,et al.  Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Tanaka,et al.  Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. , 1994, Blood.

[25]  B. Quesnel,et al.  Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. , 1994, Leukemia.

[26]  I. Frazer,et al.  Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. , 1994, The Journal of general virology.

[27]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[28]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[29]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[30]  T. Hunter,et al.  Cyclins and cancer , 1991, Cell.

[31]  P. Peebles.  An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C, and the feline--primate viruses RD-114/CCC/M-7. , 1975, Virology.

[32]  A. Okamoto,et al.  Mutations and altered expression of p 16 INK 4 in human cancer ( p 53 protein / tumor-suppressor gene / cyclin Di / retinoblastoma protein ) , 2022 .